SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-70003"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-70003" > Rapid and sustained...

Rapid and sustained relief from the symptoms of carcinoid syndrome : results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

Ruszniewski, Philippe (författare)
Ish-Shalom, Sofia (författare)
Wymenga, Machteld (författare)
visa fler...
O'Toole, Dermot (författare)
Arnold, Rudolf (författare)
Tomassetti, Paola (författare)
Bax, Nigel (författare)
Caplin, Martyn (författare)
Eriksson, Barbro (författare)
Uppsala universitet,Institutionen för medicinska vetenskaper
Glaser, Benjamin (författare)
Ducreux, Michel (författare)
Lombard-Bohas, Catherine (författare)
de Herder, Wouter W. (författare)
Delle Fave, Gianfranco (författare)
Reed, Nick (författare)
Seitz, Jean Francois (författare)
Van Cutsem, Eric (författare)
Grossman, Ashley (författare)
Rougier, Philippe (författare)
Schmidt, Wolfgang (författare)
Wiedenmann, Bertram (författare)
visa färre...
 (creator_code:org_t)
2004
2004
Engelska.
Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 80:4, s. 244-251
  • Tidskriftsartikel (övrigt vetenskapligt)
Abstract Ämnesord
Stäng  
  • This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120 mg) according to symptom response. Seventy-one patients were treated. Flushing decreased from a mean of 3.0 at baseline to 2.3 on day 1, and 2.0 on day 2, with a daily mean of 2.1 for the first week post-treatment (p < 0.05). Diarrhea decreased from a mean of 5.0 at baseline to 4.3 on day 1 (p < 0.05), and 4.5 on day 2, with a daily mean of 4.4 for the first week post-treatment (p < 0.001). Symptom frequency decreased further after the second and third injections, and reached a plateau after the fourth injection. By month 6, flushing and diarrhea had significantly decreased from baseline by a mean of 1.3 and 1.1 episodes/day, respectively (both p < or = 0.001); 65% of patients with flushing as the target symptom and 18% of diarrhea-target patients achieved > or =50% reduction from baseline. Median urinary 5-hydroxyindoleacetic acid and chromogranin A levels decreased by 24 and 38%, respectively. Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome.

Nyckelord

Adult
Aged
Aged; 80 and over
Chromogranins/blood
Comparative Study
Delayed-Action Preparations/*therapeutic use
Dose-Response Relationship; Drug
Drug Administration Schedule
Drug Evaluation/methods
Female
Flushing/drug therapy/physiopathology
Humans
Hydroxyindoleacetic Acid/urine
Male
Malignant Carcinoid Syndrome/complications/*drug therapy/metabolism
Middle Aged
Peptides; Cyclic/blood/*therapeutic use
Quality of Life
Research Support; Non-U.S. Gov't
Somatostatin/*analogs & derivatives/blood/*therapeutic use
Time Factors
Treatment Outcome
Vipoma/drug therapy/physiopathology
MEDICINE
MEDICIN

Publikations- och innehållstyp

vet (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy